Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
25.81
+0.79 (+3.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Stocks Fall As Bond Yields Hit Multi-Year Highs
↗
October 18, 2023
The major indexes are firmly lower this afternoon, with both the Dow Jones Industrial Average and Nasdaq Composite down triple digits as bond yields rise.
Via
Talk Markets
Topics
Bonds
Stocks
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 17, 2023
Via
Benzinga
Ultragenyx Announces Proposed Public Offering of Common Stock
October 17, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Why Is Mereo BioPharma Stock Trading Higher Today?
↗
October 16, 2023
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit
Via
Benzinga
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
↗
October 10, 2023
Via
Benzinga
Earnings Scheduled For August 3, 2023
↗
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
↗
August 01, 2023
Via
Benzinga
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
↗
June 06, 2023
Via
Benzinga
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
October 16, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
October 14, 2023
From
Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Why Ultragenyx Pharma Stock Is Trading Higher Premarket Today
↗
June 06, 2023
Via
Benzinga
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
October 09, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
October 05, 2023
Analyst Day will be webcast beginning at 8:30 a.m. ET on Monday, October 16
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Investor Conferences in September
August 31, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
August 03, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
July 31, 2023
Initial data expected in first half of 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
July 27, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
July 12, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
July 06, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
June 21, 2023
The company is one of the first in the U.S. with complete end-to-end gene therapy capabilities in Massachusetts, from research and development to therapeutic production at scale
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023
↗
June 06, 2023
Via
Benzinga
Apple To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Tuesday
↗
June 06, 2023
B of A Securities boosted the price target for Molson Coors Beverage Company (NYSE: TAP) from $54 to $68. B of A Securities analyst Bryan Spillane upgraded the stock from Underperform to Neutral....
Via
Benzinga
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
June 05, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
May 19, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
